

## **ImmunoGen, Inc. Announces Webcast of Presentation at the Canaccord Genuity 31st Annual Growth Conference**

WALTHAM, Mass., Aug 05, 2011 (BUSINESS WIRE) -- [ImmunoGen, Inc.](http://www.immunogen.com) (Nasdaq: IMGN), a biotechnology company that develops targeted antibody-based anticancer products using its antibody expertise and Targeted Antibody Payload (TAP) technology, today announced that its presentation at the Canaccord Genuity 31<sup>st</sup> Annual Growth Conference at 2:00 pm ET on August 11, 2011 will be webcast live.

The webcast of this presentation can be accessed live through the "Investor Information" section of the Company's website, <http://www.immunogen.com>; a replay of the presentation will be available at the same location for one week.

### **About ImmunoGen, Inc.**

ImmunoGen, Inc. develops targeted anticancer therapeutics using the Company's expertise in tumor biology, monoclonal antibodies, potent cancer-cell killing agents and engineered linkers. The Company's TAP technology uses monoclonal antibodies to deliver one of ImmunoGen's proprietary cancer-cell killing agents specifically to tumor cells. There are now numerous TAP compounds in clinical development and a wealth of clinical data reported. ImmunoGen's collaborative partners include Amgen, Bayer HealthCare Pharmaceuticals, Biotest, Novartis, Roche, and Sanofi. The most advanced compound using ImmunoGen's TAP technology, trastuzumab emtansine (T-DM1), is in Phase III testing through the Company's collaboration with Genentech, a member of the Roche Group. More information about ImmunoGen can be found at <http://www.immunogen.com>.

SOURCE: ImmunoGen, Inc.

### **For Investors:**

ImmunoGen, Inc.  
Carol Hausner, 781-895-0600  
Executive Director, Investor Relations and Corporate Communications  
[info@immunogen.com](mailto:info@immunogen.com)  
or

### **For Media:**

The Yates Network  
Barbara Yates, 781-258-6153